2012 (14)
2011 (43)
2010 (64)
2009 (52)
Government Agencies (70)
Nursing Council of New Zealand (11)
Other Agencies (65)
Select Committees (31)
The New Zealand Nurses Organisation (NZNO) actively works towards improving the health status of all peoples of Aotearoa/ New Zealand, one of the ways we do this is by making submissions on health and social policy related issues.
The New Zealand Nurses Organisation made a submission to PHARMAC on the Proposal to list Insulin Pumps and Consumables.
The New Zealand Nurses Organisation made a submission to PHARMAC on the Proposal to amend definitions of prescribe ty[pes in the Pharmaceutical Schedule and to apply these defintiions to Special Authorities.
The New Zealand Nurses organisation made a submission to Pharmac on Proposals relating to Multiple Diabetes Management Products.
25 March 2011
The New Zealand Nurses Organisation (NZNO) submitted to Pharmac on the Review of Exceptional Circumstances (consultation on proposed changes).
1 April 2010
The New Zealand Nurses Organisation (NZNO) made a submission to PHARMAC on the consultation/discussion document for possible expansion of PHARMAC’s role.
19 March 2010
The New Zealand Nurses Organisation (NZNO) made a submission to PHARMAC on the Special Foods consultation Document.
23 February 2010
The New Zealand Nurses Organisation (NZNO) responded to PHARMAC's proposal to fund gemcitabine and vinorelbine for relapsed/ refractory Hodgkin's Disease and T-Cell Lymphoma.
3 December 2009
NZNO Submission to PHARMAC on the Pharmaceutical Management Agency Consumer Participation Discussion Document.
14 AUGUST 2009
The New Zealand Nurses Organisation made a submission to PHARMAC on proposals regarding diabetes management products.
1 JULY 2009
The New Zealand Nurses Organisation made a submission to PHARMAC on the Draft Guidelines for Funding Applications.
20 April 2009
Diabetes Nurse Specialist Section of NZNO made a submission on Proposals regarding multiple diabetes management products.
08 April 2009
NZNO wrote a letter in response to PHARMAC’s proposal to widen access to Rituximab.